EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Mark N Stein iD, Armelle Vinceneux, Debbie Robbrecht iD, Bernard Doger, Karen A Autio iD, Michael T Schweizer, Emiliano Calvo iD, Laura Medina, Marloes Van Dongen, Jean-Laurent Deville iD, Alice Bernard-Tessier, Debopriya Ghosh und 12 weitere

Journal of Clinical Oncology · 2025-08 · 43 (22) · 2515-2526

DOI: 10.1200/jco-25-00678 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2025-08. Verfasst von Mark N Stein und 23 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Medical Center, New York, NY. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antibodies, Bispecific, T-Lymphocytes, Kallikreins. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE We report phase I trial results for pasritamig, a first-in-class, T-cell–engaging bispecific antibody targeting human kallikrein 2 (KLK2) expressed on the surface of prostate cancer (PC) cells. METHODS Participants had metastatic castration-resistant PC and ≥1 prior therapy. Pasritamig was escalated from 0.5 mg to 2,000 mg for subcutaneous administration and from 150 mg to 900 mg for intravenous (IV) administration at dosing frequencies ranging from once every week to once every 6 weeks with different step-up dosing schedules. The primary objectives were to determine safety and the recommended phase II dose (RP2D) of pasritamig. Secondary objectives included preliminary assessment of antitumor activity. RESULTS One hundred seventy-four participants received pasritamig, with a median of 4 prior lines of systemic therapy. Treatment-related adverse events (TRAEs) occurred in 144 of 174 (82.8%) participants, with 17 of 174 (9.8%) experiencing grade ≥3 TRAEs. The RP2D was determined to be 3.5 mg (day 1), 18 mg (day 8), 300 mg (day 15), and then 300 mg IV once every 6 weeks. In the RP2D safety population (n = 45), infusion-related reactions (11/45, 24.4%), fatigue (7/45, 15.6%), cytokine release syndrome (CRS; 4/45, 8.9%, all grade 1), and lipase increase (4/45, 8.9%) were the most frequent TRAEs; all were grade 1 or 2. In the RP2D efficacy population (n = 33), median radiographic progression-free survival was 7.85 (95% CI, 2.89 to not estimable) months, and 14 of 33 (42.4%) participants achieved a ≥50% decrease from baseline in prostate-specific antigen. CONCLUSION Pasritamig demonstrated a favorable safety profile with very low rates of CRS and could be safely administered in an outpatient setting. Preliminary antitumor activity demonstrated proof of concept for KLK2 as a target in PC, warranting further development of pasritamig.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAntibodies, BispecificT-LymphocytesKallikreinsTissue KallikreinsHumansMaleAgedMiddle AgedAged, 80 and over

Substanzen

Antibodies, BispecificKallikreinsKLK2 protein, humanTissue Kallikreins

Autor:innen und Institutionen

  • Columbia University Medical Center, New York, NY.
  • Centre Léon Bérard, Lyon, France.
  • Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain.
  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.

ORCID-Profile: Mark N Stein, Debbie Robbrecht, Karen A Autio, Emiliano Calvo, Jean-Laurent Deville, Kristin Shotts, Pharavee Jaiprasart, Josh Lauring, Sherry C Wang, Victor M Villalobos, Capucine Baldini

Förderung

  • NCI NIH HHS

Zitieren

APA

Stein, M. N., Vinceneux, A., Robbrecht, D., Doger, B., Autio, K. A., Schweizer, M. T., Calvo, E., Medina, L., Van Dongen, M., Deville, J. L., Bernard-Tessier, A., Ghosh, D., Shotts, K., Shen, F., Jaiprasart, P., Chaudhary, R., Wu, S., Cartee, L., Schnepp, R., …, & Baldini, C. (2025). Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Journal of Clinical Oncology, 43(22), 2515-2526. https://doi.org/10.1200/jco-25-00678

Vancouver

Stein MN, Vinceneux A, Robbrecht D, Doger B, Autio KA, Schweizer MT, et al. Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Journal of Clinical Oncology. 2025;43(22):2515-2526. doi:10.1200/jco-25-00678

BibTeX
@article{Stein2025,
  author = {Stein, Mark N and Vinceneux, Armelle and Robbrecht, Debbie and Doger, Bernard and Autio, Karen A and Schweizer, Michael T and Calvo, Emiliano and Medina, Laura and Van Dongen, Marloes and Deville, Jean-Laurent and Bernard-Tessier, Alice and Ghosh, Debopriya and Shotts, Kristin and Shen, Fei and Jaiprasart, Pharavee and Chaudhary, Ruchi and Wu, Shujian and Cartee, Leanne and Schnepp, Robert and Gaut, Daria and Lauring, Josh and Wang, Sherry C and Villalobos, Victor M and Baldini, Capucine},
  title = {Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {22},
  pages = {2515--2526},
  doi = {10.1200/jco-25-00678}
}
Kostenlos starten →